Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP2015 vs Enbrel in moderate to severe rheumatoid arthritis
2012-002009-23Phase 3Completed
- Sponsor
- Hexal AG
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omalizumab biosimilar SYN008 in rheumatoid arthritis (RA) (2 arms), sponsored by Hexal AG. Primary endpoint: Change from baseline in DAS28-CRP. Started Sep 2015; status: completed.
02
Drugs
omalizumab biosimilar SYN008
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-002009-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002009-23.